Astec LifeSciences Q4 Revenue Up 34% YoY

• Astec LifeSciences reported Q4 FY26 consolidated revenue of ₹161.3 crore, up 34% year-over-year.
• The company achieved EBITDA of ₹11.8 crore in Q4 FY26, an 87% increase from Q4 FY25.
• Full-year FY26 showed significant improvement with EBITDA breakeven versus a ₹60.6 crore loss in FY25.
• Performance driven by improved volumes in both Enterprise and Contract Manufacturing segments.